Outwitting evolution: Fighting drug-resistant TB, Malaria, and HIV

Cell

Volumn 148, Issue 6, 2012, Pages 1271-1283

  Goldberg, Daniel E ^a   Siliciano, Robert F ^b   Jacobs, William R ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIRETROVIRUS AGENT; BEDAQUILINE; DELAMANID; LL 3858; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMETHAMINE; QUINOLINE; SULFADOXINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG RESISTANCE; DRUG RESISTANT TUBERCULOSIS; DRUG TOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALARIA; NONHUMAN; PHENOTYPE; PLASMODIUM; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858389346     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.02.021     Document Type: Review

References (119)

1. A.J. Acosta-Hoyos, and W.A. Scott The role of nucleotide excision by reverse transcriptase in HIV drug resistance Viruses 2 2010 372 394
2. K.N. Adams, K. Takaki, L.E. Connolly, H. Wiedenhoft, K. Winglee, O. Humbert, P.H. Edelstein, C.L. Cosma, and L. Ramakrishnan Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism Cell 145 2011 39 53
3. Z. Ahmad, N.H. Makaya, and J. Grosset P.R. Donald, P.D. Helden, C.T. Bolliger, Antituberculosis Chemotherapy Volume 40 2011 S. Karger Pub Basel, NY 1 8
4. D. Almeida, E. Nuermberger, R. Tasneen, I. Rosenthal, S. Tyagi, K. Williams, C. Peloquin, and J. Grosset Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis Antimicrob. Agents Chemother. 53 2009 4178 4184
5. T.J. Anderson, J. Patel, and M.T. Ferdig Gene copy number and malaria biology Trends Parasitol. 25 2009 336 343
6. J.R. Andrews, N.R. Gandhi, P. Moodley, N.S. Shah, L. Bohlken, A.P. Moll, M. Pillay, G. Friedland, A.W. Sturm Tugela Ferry Care and Research Collaboration Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa J. Infect. Dis. 198 2008 1582 1589
7. K. Andries, P. Verhasselt, J. Guillemont, H.W. Göhlmann, J.M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, and E. Lee A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
8. D.R. Bangsberg, E.P. Acosta, R. Gupta, D. Guzman, E.D. Riley, P.R. Harrigan, N. Parkin, and S.G. Deeks Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness AIDS 20 2006 223 231
9. W.F. Bierman, M.A. van Agtmael, M. Nijhuis, S.A. Danner, and C.A. Boucher HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review AIDS 23 2009 279 291
10. BMRC STREPTOMYCIN treatment of pulmonary tuberculosis BMJ 2 1948 769 782
11. BMRC TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation BMJ 2 1950 1073 1085
12. BMRC TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee BMJ 2 1952 735 746
13. S. Bonhoeffer, and M.A. Nowak Pre-existence and emergence of drug resistance in HIV-1 infection Proc. Biol. Sci. 264 1997 631 637
14. T. Bousema, and C. Drakeley Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination Clin. Microbiol. Rev. 24 2011 377 410
15. M.A. Boyd Improvements in antiretroviral therapy outcomes over calendar time Curr. Opin. HIV AIDS 4 2009 194 199
16. P.G. Bray, R.E. Martin, L. Tilley, S.A. Ward, K. Kirk, and D.A. Fidock Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance Mol. Microbiol. 56 2005 323 333
17. Centers for Disease Control and Prevention (CDC) Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin MMWR Morb. Mortal. Wkly. Rep. 45 1996 921 925
18. S. Clark, C. Calef, and J. Mellors Mutations in retroviral genes associated with drug resistance T. Leitner, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, B. Korber, HIV Sequence Compendium 2007 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory Los Alamos, NM 58 158
19. F. Clavel, and A.J. Hance HIV drug resistance N. Engl. J. Med. 350 2004 1023 1035
20. J.M. Coffin HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 1995 483 489
21. R.A. Cooper, M.T. Ferdig, X.Z. Su, L.M. Ursos, J. Mu, T. Nomura, H. Fujioka, D.A. Fidock, P.D. Roepe, and T.E. Wellems Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum Mol. Pharmacol. 61 2002 35 42
22. K.H. Darwin, S. Ehrt, J.C. Gutierrez-Ramos, N. Weich, and C.F. Nathan The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide Science 302 2003 1963 1966
23. S.G. Deeks, S.J. Gange, M.M. Kitahata, M.S. Saag, A.C. Justice, R.S. Hogg, J.J. Eron, J.T. Brooks, S.B. Rourke, and M.J. Gill Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America Clin. Infect. Dis. 49 2009 1582 1590
24. P.J. de Vries, and T.K. Dien Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria Drugs 52 1996 818 836
25. J.M. Dickinson, V.R. Aber, and D.A. Mitchison Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis Am. Rev. Respir. Dis. 116 1977 627 635
26. A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, and S.J. Lee Artemisinin resistance in Plasmodium falciparum malaria N. Engl. J. Med. 361 2009 455 467
27. E. Dunner, W.B. Brown, and J. Wallace The effect of streptomycin with para-amino salicylic acid on the emergence of resistant strains of tubercle bacilli Dis. Chest 16 1949 661 666
28. EA/BMRC Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis Lancet 1 1972 1079 1085
29. D.A. Fidock, T. Nomura, A.K. Talley, R.A. Cooper, S.M. Dzekunov, M.T. Ferdig, L.M. Ursos, A.B. Sidhu, B. Naudé, and K.W. Deitsch Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance Mol. Cell 6 2000 861 871
30. T.S. Flys, D. Donnell, A. Mwatha, C. Nakabiito, P. Musoke, F. Mmiro, J.B. Jackson, L.A. Guay, and S.H. Eshleman Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission J. Infect. Dis. 195 2007 711 715
31. C.B. Ford, P.L. Lin, M.R. Chase, R.R. Shah, O. Iartchouk, J. Galagan, N. Mohaideen, T.R. Ioerger, J.C. Sacchettini, and M. Lipsitch Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection Nat. Genet. 43 2011 482 486
32. N.R. Gandhi, P. Nunn, K. Dheda, H.S. Schaaf, M. Zignol, D. van Soolingen, P. Jensen, and J. Bayona Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis Lancet 375 2010 1830 1843
33. S. Gandotra, D. Schnappinger, M. Monteleone, W. Hillen, and S. Ehrt In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice Nat. Med. 13 2007 1515 1520
34. O. Gil, I. Díaz, C. Vilaplana, G. Tapia, J. Díaz, M. Fort, N. Cáceres, S. Pinto, J. Caylà, and L. Corner Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs PLoS ONE 5 2010 e10030
35. W.P. Gill, N.S. Harik, M.R. Whiddon, R.P. Liao, J.E. Mittler, and D.R. Sherman A replication clock for Mycobacterium tuberculosis Nat. Med. 15 2009 211 214
36. A. Ginsberg The TB Alliance: overcoming challenges to chart the future course of TB drug development Future Med Chem 3 2011 1247 1252
37. J. Grosset, C. Truffot-Pernot, C. Lacroix, and B. Ji Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice Antimicrob. Agents Chemother. 36 1992 548 551
38. E. Guantai, and K. Chibale Chloroquine resistance: proposed mechanisms and countermeasures Curr. Drug Deliv. 7 2010 312 323
39. L.A. Guay, P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, and M. Deseyve Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Lancet 354 1999 795 802
40. R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, D.D. Richman, F.T. Valentine, L. Jonas, and A. Meibohm Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N. Engl. J. Med. 337 1997 734 739
41. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, J.S. Currier, J.J. Eron Jr., J.E. Feinberg, H.H. Balfour Jr., and L.R. Deyton A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N. Engl. J. Med. 337 1997 725 733
42. W.E. Harrington, T.K. Mutabingwa, A. Muehlenbachs, B. Sorensen, M.C. Bolla, M. Fried, and P.E. Duffy Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment Proc. Natl. Acad. Sci. USA 106 2009 9027 9032
43. H.C. Hinshaw, W.H. Feldman, and K.H. Pfuetze Treatment of tuberculosis with streptomycin; a summary of observations on one hundred cases J. Am. Med. Assoc. 132 1946 778 782
44. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
45. J.E. Hyde Drug-resistant malaria Trends Parasitol. 21 2005 494 498
46. E.S. Istvan, N.V. Dharia, S.E. Bopp, I. Gluzman, E.A. Winzeler, and D.E. Goldberg Validation of isoleucine utilization targets in Plasmodium falciparum Proc. Natl. Acad. Sci. USA 108 2011 1627 1632
47. B.L. Jilek, M. Zarr, M. Sampah, S.A. Rabi, C.K. Bullen, J. Lai, L. Shen, and R.F. Siliciano A quantitative basis for antiretroviral therapy for HIV-1 infection Nat. Med. 2012 10.1038/nm.2649 Published online February 19 2012
48. R. Johnson, E.M. Streicher, G.E. Louw, R.M. Warren, P.D. van Helden, and T.C. Victor Drug resistance in Mycobacterium tuberculosis Curr. Issues Mol. Biol. 8 2006 97 111
49. V.A. Johnson, F. Brun-Vézinet, B. Clotet, H.F. Günthard, D.R. Kuritzkes, D. Pillay, J.M. Schapiro, and D.D. Richman Update of the drug resistance mutations in HIV-1: December 2010 Top. HIV Med. 18 2010 156 163
50. T. Kaneko, C. Cooper, and K. Mdluli Challenges and opportunities in developing novel drugs for TB Future Med Chem 3 2011 1373 1400
51. B.F. Keele, E.E. Giorgi, J.F. Salazar-Gonzalez, J.M. Decker, K.T. Pham, M.G. Salazar, C. Sun, T. Grayson, S. Wang, and H. Li Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection Proc. Natl. Acad. Sci. USA 105 2008 7552 7557
52. J.B. Koenderink, R.A. Kavishe, S.R. Rijpma, and F.G. Russel The ABCs of multidrug resistance in malaria Trends Parasitol. 26 2010 440 446
53. A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van den Wyngaert, K. Vergauwen, H.W. Göhlmann, R. Willebrords, A. Poncelet, and J. Guillemont Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 283 2008 25273 25280
54. L. Krishnan, X. Li, H.L. Naraharisetty, S. Hare, P. Cherepanov, and A. Engelman Structure-based modeling of the functional HIV-1 intasome and its inhibition Proc. Natl. Acad. Sci. USA 107 2010 15910 15915
55. B.A. Larder, G. Darby, and D.D. Richman HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy Science 243 1989 1731 1734
56. M.K. Laufer, P.C. Thesing, N.D. Eddington, R. Masonga, F.K. Dzinjalamala, S.L. Takala, T.E. Taylor, and C.V. Plowe Return of chloroquine antimalarial efficacy in Malawi N. Engl. J. Med. 355 2006 1959 1966
57. J. Lehmann Para-aminosalicylic acid in the treatment of tuberculosis Lancet 1 1946 15
58. S.J. Little, A.R. McLean, C.A. Spina, D.D. Richman, and D.V. Havlir Viral dynamics of acute HIV-1 infection J. Exp. Med. 190 1999 841 850
59. S.J. Little, S. Holte, J.P. Routy, E.S. Daar, M. Markowitz, A.C. Collier, R.A. Koup, J.W. Mellors, E. Connick, and B. Conway Antiretroviral-drug resistance among patients recently infected with HIV N. Engl. J. Med. 347 2002 385 394
60. G. Lin, D. Li, L.P. de Carvalho, H. Deng, H. Tao, G. Vogt, K. Wu, J. Schneider, T. Chidawanyika, and J.D. Warren Inhibitors selective for mycobacterial versus human proteasomes Nature 461 2009 621 626
61. M.A. Lobritz, A.N. Ratcliff, and E.J. Arts HIV entry, inhibitors, and resistance Viruses 2 2010 1069 1105
62. L.M. Mansky, and H.M. Temin Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase J. Virol. 69 1995 5087 5094
63. S. Margeridon-Thermet, and R.W. Shafer Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C Viruses 2 2010 2696 2739
64. R.E. Martin, R.V. Marchetti, A.I. Cowan, S.M. Howitt, S. Bröer, and K. Kirk Chloroquine transport via the malaria parasite's chloroquine resistance transporter Science 325 2009 1680 1682
65. V. Mathys, R. Wintjens, P. Lefevre, J. Bertout, A. Singhal, M. Kiass, N. Kurepina, X.M. Wang, B. Mathema, and A. Baulard Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 53 2009 2100 2109
66. R.M. McCune Jr., and R. Tompsett Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy J. Exp. Med. 104 1956 737 762
67. R.M. McCune Jr., W. McDermott, and R. Tompsett The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug J. Exp. Med. 104 1956 763 802
68. R.M. McCune, F.M. Feldmann, H.P. Lambert, and W. McDermott Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues J. Exp. Med. 123 1966 445 468
69. I.B. Müller, and J.E. Hyde Antimalarial drugs: modes of action and mechanisms of parasite resistance Future Microbiol. 5 2010 1857 1873
70. T. Nomura, J.M. Carlton, J.K. Baird, H.A. del Portillo, D.J. Fryauff, D. Rathore, D.A. Fidock, X. Su, W.E. Collins, and T.F. McCutchan Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria J. Infect. Dis. 183 2001 1653 1661
71. M.A. Nowak, A.L. Lloyd, G.M. Vasquez, T.A. Wiltrout, L.M. Wahl, N. Bischofberger, J. Williams, A. Kinter, A.S. Fauci, V.M. Hirsch, and J.D. Lifson Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection J. Virol. 71 1997 7518 7525
72. M.L. Ntemgwa, T. d'Aquin Toni, B.G. Brenner, R.J. Camacho, and M.A. Wainberg Antiretroviral drug resistance in human immunodeficiency virus type 2 Antimicrob. Agents Chemother. 53 2009 3611 3619
73. C.F. Ockenhouse, A. Magill, D. Smith, and W. Milhous History of U.S. military contributions to the study of malaria Mil. Med. 170 Suppl 4 2005 12 16
74. S. Palmer, M. Kearney, F. Maldarelli, E.K. Halvas, C.J. Bixby, H. Bazmi, D. Rock, J. Falloon, R.T. Davey Jr., and R.L. Dewar Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis J. Clin. Microbiol. 43 2005 406 413
75. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.Aidsinfo.Nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 1-161.
76. D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, C. Squier, M.M. Wagener, and N. Singh Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann. Intern. Med. 133 2000 21 30
77. D. Payne Spread of chloroquine resistance in Plasmodium falciparum Parasitol. Today (Regul. Ed.) 3 1987 241 246
78. A.S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D.D. Ho Decay characteristics of HIV-1-infected compartments during combination therapy Nature 387 1997 188 191
79. C.J. Petropoulos, N.T. Parkin, K.L. Limoli, Y.S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G.A. Winslow, D.J. Capon, and J.M. Whitcomb A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 44 2000 920 928
80. A.V. Pichugin, B.S. Yan, A. Sloutsky, L. Kobzik, and I. Kramnik Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts Am. J. Pathol. 174 2009 2190 2201
81. M.E. Quiñones-Mateu, and E.J. Arts C. Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J.W. Mellors, S. Wolinsky, B. Korber, HIV-1 Fitness: Implications for Drug Resistance, Disease Progression, and Global Epidemic Evolution 2001 Theoretical Biology and Biophysics Group, Los Alamos National Laboratory Los Alamos, NM 134 170
82. P.K. Rathod Antimalarial agents directed at thymidylate synthase J. Pharm. Pharmacol. 49 1997 65 69
83. F. Rocco The Miraculous Fever-Tree: The Cure that Changed the World 2004 Harper Collins San Francisco, CA
84. C. Roper, R. Pearce, B. Bredenkamp, J. Gumede, C. Drakeley, F. Mosha, D. Chandramohan, and B. Sharp Antifolate antimalarial resistance in southeast Africa: a population-based analysis Lancet 361 2003 1174 1181
85. V.K. Sambandamurthy, X. Wang, B. Chen, R.G. Russell, S. Derrick, F.M. Collins, S.L. Morris, and W.R. Jacobs Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis Nat. Med. 8 2002 1171 1174
86. M.E. Sampah, L. Shen, B.L. Jilek, and R.F. Siliciano Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance Proc. Natl. Acad. Sci. USA 108 2011 7613 7618
87. S.G. Sarafianos, K. Das, S.H. Hughes, and E. Arnold Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases Curr. Opin. Struct. Biol. 14 2004 716 730
88. A. Schatz, and S. Waksman Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria Proc. Soc. Exp. Biol. Med. 55 1944 66 69
89. R. Schuurman, M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S.A. Danner, J. Mulder, C. Loveday, and C. Christopherson Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) J. Infect. Dis. 171 1995 1411 1419
90. A.K. Sethi, D.D. Celentano, S.J. Gange, R.D. Moore, and J.E. Gallant Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance Clin. Infect. Dis. 37 2003 1112 1118
91. R.W. Shafer Genotypic testing for human immunodeficiency virus type 1 drug resistance Clin. Microbiol. Rev. 15 2002 247 277
92. R. Shankarappa, J.B. Margolick, S.J. Gange, A.G. Rodrigo, D. Upchurch, H. Farzadegan, P. Gupta, C.R. Rinaldo, G.H. Learn, and X. He Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection J. Virol. 73 1999 10489 10502
93. L. Shen, S. Peterson, A.R. Sedaghat, M.A. McMahon, M. Callender, H. Zhang, Y. Zhou, E. Pitt, K.S. Anderson, E.P. Acosta, and R.F. Siliciano Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs Nat. Med. 14 2008 762 766
94. L. Shen, S.A. Rabi, A.R. Sedaghat, L. Shan, J. Lai, S. Xing, and R.F. Siliciano A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs Sci. Transl. Med. 3 2011 91ra63
95. W. Shi, X. Zhang, X. Jiang, H. Yuan, J.S. Lee, C.E. Barry 3rd, H. Wang, W. Zhang, and Y. Zhang Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632
96. K. Slavic, M.J. Delves, M. Prudêncio, A.M. Talman, U. Straschil, E.T. Derbyshire, Z. Xu, R.E. Sinden, M.M. Mota, and C. Morin Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite's life cycle Antimicrob. Agents Chemother. 55 2011 2824 2830
97. M.K. Spigelman New tuberculosis therapeutics: a growing pipeline J. Infect. Dis. 196 Suppl 1 2007 S28 S34
98. S. Sreevatsan, K.E. Stockbauer, X. Pan, B.N. Kreiswirth, S.L. Moghazeh, W.R. Jacobs Jr., A. Telenti, and J.M. Musser Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations Antimicrob. Agents Chemother. 41 1997 1677 1681
99. S. Srivastava, S. Musuka, C. Sherman, C. Meek, R. Leff, and T. Gumbo Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol J. Infect. Dis. 201 2010 1225 1231
100. S. Srivastava, C. Sherman, C. Meek, R. Leff, and T. Gumbo Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling Antimicrob. Agents Chemother. 55 2011 5085 5089
101. H.C. Sweany, G.C. Turner, M. Lichtenstein, and S. Entin A preliminary report on the use of para-amino salicylic acid in the treatment of pulmonary tuberculosis Dis. Chest 16 1949 633 660, illust
102. K. Takayama, and J.O. Kilburn Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis Antimicrob. Agents Chemother. 33 1989 1493 1499
103. F. Teuscher, M.L. Gatton, N. Chen, J. Peters, D.E. Kyle, and Q. Cheng Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure J. Infect. Dis. 202 2010 1362 1368
104. J.P. Thomas, C.O. Baughn, R.G. Wilkinson, and R.G. Shepherd A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2′-(ethylenediimino)-di-l-butanol) Am. Rev. Respir. Dis. 83 1961 891 893
105. M.A. Thompson, J.A. Aberg, P. Cahn, J.S. Montaner, G. Rizzardini, A. Telenti, J.M. Gatell, H.F. Günthard, S.M. Hammer, M.S. Hirsch International AIDS Society-USA Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 2010 321 333
106. Y. Tu The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine Nat. Med. 17 2011 1217 1220
107. A.B. Vaidya, and M.W. Mather Atovaquone resistance in malaria parasites Drug Resist. Updat. 3 2000 283 287
108. C. Vilchze, and W.R. Jacobs Jr. The mechanism of isoniazid killing: clarity through the scope of genetics Annu. Rev. Microbiol. 61 2007 35 50
109. C. Vilchze, F. Wang, M. Arai, M.H. Hazbón, R. Colangeli, L. Kremer, T.R. Weisbrod, D. Alland, J.C. Sacchettini, and W.R. Jacobs Jr. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid Nat. Med. 12 2006 1027 1029
110. S. Vinayak, M.T. Alam, T. Mixson-Hayden, A.M. McCollum, R. Sem, N.K. Shah, P. Lim, S. Muth, W.O. Rogers, and T. Fandeur Origin and evolution of sulfadoxine resistant Plasmodium falciparum PLoS Pathog. 6 2010 e1000830
111. X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, and B.H. Hahn Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122
112. A.M. Wensing, N.M. van Maarseveen, and M. Nijhuis Fifteen years of HIV protease inhibitors: raising the barrier to resistance Antiviral Res. 85 2010 59 74
113. W.H. Wheeler, R.A. Ziebell, H. Zabina, D. Pieniazek, J. Prejean, U.R. Bodnar, K.C. Mahle, W. Heneine, J.A. Johnson, H.I. Hall Variant, Atypical, and Resistant HIV Surveillance Group Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006 AIDS 24 2010 1203 1212
114. N.J. White Antimalarial drug resistance J. Clin. Invest. 113 2004 1084 1092
115. WHO Multidrug and Extensively Drug-Resistant Tuberculosis: 2010 Global Report on Surveillance and Response 2010 World Health Organization Geneva, Switzerland
116. D. Wodarz, and M.A. Nowak Mathematical models of HIV pathogenesis and treatment Bioessays 24 2002 1178 1187
117. R.L. Yeager, W.G. Munroe, and F.I. Dessau Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis Am. Rev. Tuberc. 65 1952 523 546
118. M. Zhang, S.Y. Li, I.M. Rosenthal, D.V. Almeida, Z. Ahmad, P.J. Converse, C.A. Peloquin, E.L. Nuermberger, and J.H. Grosset Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice Am. J. Respir. Crit. Care Med. 183 2011 1254 1261
119. O. Zimhony, J.S. Cox, J.T. Welch, C. Vilchze, and W.R. Jacobs Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis Nat. Med. 6 2000 1043 1047